** Biocon BION.NS climbs 4.4% to 332.80 rupees
** Drugmaker's unit Biocon Biologics gets marketing access for its immunotherapy drug Yesintek - Biocon's biosimilar for Janssen Biotech's Stelara - in the U.S.
** The therapy, chemically called ustekinumab, is used for treating patients with chronic plaque psoriasis
** Stock rated "buy" on avg; median PT is 400 rupees, per data compiled by LSEG
** Session's gains trim BION's YTD losses to 8.9%
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.